Research programme: antibacterials - BayerAlternative Names: 6-Aminouracil-DNA polymerase inhibitors research programme - Bayer; Antibacterials research programme - Bayer; DNA polymerase inhibitors research programme - Bayer; Phe-RS inhibitors research programme – Bayer; Phenylalanyl-tRNA synthetase inhibitors research programme – Bayer
Latest Information Update: 24 Mar 2010
At a glance
- Originator Bayer
- Developer GeneData
- Class Sulfonamides
- Mechanism of Action Enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections